Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177 XT381 in PSMA-positive metastatic castration-resistant prostate cancer (Ib/II, China)
CTR20263248Phase 2Active
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of [177Lu]Lu-XT381 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sinotau Pharmaceutical Group. Started Aug 2026; status: active.
02
Drugs
[177Lu]Lu-XT381
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20263248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263248.